logo

Celyad Sa (CYAD)



Trade CYAD now with
  Date
  Headline
1/7/2019 1:03:59 AM Celyad Outlines Key 2019 Priorities Including Acceleration Of CYAD-01 Program In R/r AML And MDS
12/4/2018 1:45:22 AM Celyad Presents Update On CYAD-01 Hematological Malignancies Clinical Program At 60th ASH Annual Meeting
11/30/2018 1:01:11 AM Celyad Doses First MCRC Patient In Phase 1 AlloSHRINK Trial On Non-Gene Edited Allogeneic CAR-T Candidate, CYAD-101
11/21/2018 1:09:36 AM Celyad Announces Q3 Business Update
10/4/2018 1:02:11 AM Celyad To Present CYAD-01 Solid Tumor Clinical Updates And Pre-Clinical Pipeline Data At The 2018 SITC Annual Meeting
10/4/2018 1:01:21 AM Celyad Announces Exclusive Agreement With Horizon Discovery Group For Use Of Its ShRNA Technology
9/28/2018 1:02:12 AM Celyad Gets Transparency Notification Of Victory Capital Management
9/26/2018 1:02:06 AM Celyad Appoints Carri Duncan As VP Corporate Development & Communications
9/5/2018 1:00:43 AM Celyad Says Successfully Doses First Colorectal Cancer Patient With CYAD-01 Following Preconditioning Chemotherapy
8/23/2018 1:23:58 AM Celyad H1 Loss Per Share EUR 1.79 Vs Loss EUR 1.52 Prior Year
8/23/2018 1:03:11 AM Celyad H1 Loss Per Share EUR 1.79 Vs Loss EUR 1.52 Last Year
7/24/2018 1:05:03 AM Celyad Announces FDA Acceptance Of IND Application For CYAD-101
6/19/2018 1:00:33 AM Celyad Advances THINK Trial To Third And Final Dose Level In Hematological Study Arm
5/23/2018 1:01:23 AM Celyad Announces Closing Of Global Offering Of 2.07 Mln Shares
5/17/2018 9:18:06 AM Celyad Announces Pricing Of $47.3 Mln Global Offering
3/29/2018 1:01:06 AM Celyad To Present Updates On CYAD-01 At AACR Annual Meeting 2018